Urogen Pharma (NASDAQ:URGN) Stock Keeps “Buy” Rating at HC Wainwright

Urogen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $75.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 123.11% from the company’s previous close.

Several other equities research analysts also recently issued reports on URGN. TD Cowen raised their price target on Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. UBS Group reiterated a “buy” rating on shares of Urogen Pharma in a research note on Thursday, July 9th. Guggenheim boosted their price objective on Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Oppenheimer boosted their price objective on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. Finally, Jefferies Financial Group restated a “buy” rating and set a $56.00 target price on shares of Urogen Pharma in a research note on Thursday, September 10th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Urogen Pharma presently has an average rating of “Moderate Buy” and a consensus target price of $52.38.

Urogen Pharma Price Performance

NASDAQ:URGN traded down $0.94 during midday trading on Monday, reaching $33.62. The stock had a trading volume of 121,215 shares, compared to its average volume of 821,223. Urogen Pharma has a 1-year low of $16.36 and a 1-year high of $50.81. The firm’s fifty day simple moving average is $43.16 and its 200-day simple moving average is $35.39. The stock has a market capitalization of $1.64 billion, a P/E ratio of -17.00 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $72.46 million for the quarter, compared to analysts’ expectations of $63.55 million. On average, equities research analysts anticipate that Urogen Pharma will post -0.20 earnings per share for the current fiscal year.

Insider Transactions at Urogen Pharma

In related news, insider Mark Schoenberg sold 871 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $42.92, for a total transaction of $37,383.32. Following the transaction, the insider owned 59,882 shares of the company’s stock, valued at approximately $2,570,135.44. The trade was a 1.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel Jason Smith sold 1,519 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total transaction of $64,618.26. Following the transaction, the general counsel directly owned 53,141 shares in the company, valued at $2,260,618.14. This trade represents a 2.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 65,269 shares of company stock worth $3,037,646. Insiders own 4.80% of the company’s stock.

Institutional Trading of Urogen Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of URGN. Partners Capital Investment Group LLP bought a new position in shares of Urogen Pharma during the 2nd quarter worth about $566,000. Legal & General Group Plc bought a new stake in shares of Urogen Pharma in the second quarter valued at about $1,319,000. California State Teachers Retirement System lifted its stake in shares of Urogen Pharma by 1,605.5% in the first quarter. California State Teachers Retirement System now owns 38,750 shares of the company’s stock valued at $697,000 after buying an additional 36,478 shares during the period. Rice Hall James & Associates LLC bought a new stake in shares of Urogen Pharma in the second quarter valued at about $11,064,000. Finally, Elmind Capital LP bought a new stake in shares of Urogen Pharma in the second quarter valued at about $4,416,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Urogen Pharma Company Profile

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company’s platform is based on RTGel, a proprietary reverse-thermal hydrogel designed to retain medicines in the urinary tract and provide localized treatment while limiting systemic exposure.

UroGen’s lead commercial product is JELMYTO (mitomycin), a gel-based therapy approved by the U.S. Food and Drug Administration for the primary chemoablation of low-grade upper tract urothelial cancer in adults.